Open source drug discovery for the developing world

Lori Mehen, an account manager at Red Hat, writes in that the future of pharma is open source--particularly when it comes to drug development for the developing world. She mentions, in particular, tuberculosis and malaria, which continue to kill in large numbers in the developing world, but for which big pharma does not have much of an interest in developing drugs, Mehen asserts. "The current approach to drug development takes too long, costs too much, and is too unpredictable for pharma to invest in small to non-existent commercial markets. So for diseases like these, open source drug development has become one of the most promising avenues and we're finding more who seem to agree." Among other efforts, she cites the Open Source Drug Discovery Network, which has established a 2,000-plus member open source platform for both computational and experimental technologies. More from MehenOpen Source Drug Discovery Network

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.